• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    KORU Medical Systems Appoints Brent Rutland as Vice President of Medical Affairs

    10/12/22 7:01:00 AM ET
    $KRMD
    Medical/Dental Instruments
    Health Care
    Get the next $KRMD alert in real time by email

    KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development of innovative and easy-to-use subcutaneous (SQ) infusion solutions, today announced the appointment of Brent Rutland as the Company's new Vice President of Medical Affairs. Mr. Rutland will provide leadership in the Company's clinical and data generation strategies, key opinion leader engagement, assessing new subcutaneous drug candidates for use with the Company's products and overseeing the medical affairs team. Additionally, Mr. Rutland will be the clinical resource for the Company's efforts in regulatory submissions, failure modes and effects analysis, health hazard evaluations, human factors design, new product development and clinical evaluation updates.

    "We are excited to bring Brent's competence to the organization – his background was a perfect fit. His expertise will advance clinical evidence generation in support of our product pipeline, provide valuable insight to our drug therapy candidates and help develop important key opinion leader relationships," said Linda Tharby, President and CEO. "Brent has helped build multiple data and clinical strategies, internal teams, and external networks in his past. His deep industry experience and passion for the patient, will make him an impactful contributor to the Company's strategy."

    Mr. Rutland's career history spans an impressive 27 years and includes working with Baxter Healthcare as a Senior Medical Science Liaison and most recently with La Jolla Pharmaceutical Company as a Senior Director, Health Outcomes. During his career he helped launch 7 vaccines, 4 drugs and 1 device. Most notably, Brent aided Baxter in the launch of Hylenex for SQ rehydration where he also helped build the Medical Affairs department. He has received several awards throughout his career, with the most recent being the President's Circle Award for Medical Affairs at La Jolla. Brent holds a Bachelor of Science degree from Texas A&M University, an MBA in Global Management from the University of Houston, and his Master of Public Health from the University of North Carolina in Epidemiology.

    "I was immediately drawn to the opportunity to work at KORU Medical as I saw the potential for future growth supported by building out the medical science and the team," said Brent Rutland, Vice President of Medical Affairs. "Medical affairs helps fulfill the unmet needs of the patient through the generation and delivery of scientific evidence to various key outside stakeholders. I look forward to developing a collaborative strategy to support the Company's overall goals."

    About KORU Medical

    KORU Medical develops, manufactures, and commercializes innovative and easy-to-use subcutaneous infusion solutions that improve quality of life for patients around the world. The FREEDOM Syringe Infusion System (the "Freedom System") currently includes the FREEDOM60® and FreedomEdge® Syringe Infusion Drivers, Precision Flow Rate Tubing™ and HIgH-Flo Subcutaneous Safety Needle Sets™. These devices are used for infusions administered in the home and alternate care settings. For more information, please visit www.korumedical.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20221012005457/en/

    Get the next $KRMD alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $KRMD

    DatePrice TargetRatingAnalyst
    2/14/2025$4.50Overweight → Neutral
    Piper Sandler
    7/25/2024$4.00Buy
    B. Riley Securities
    9/7/2023$4.00Buy
    Lake Street
    9/7/2023$4.50Buy
    B. Riley Securities
    11/10/2022$3.00 → $4.00Hold → Buy
    Canaccord Genuity
    11/10/2022$3.00 → $3.50Neutral → Overweight
    Piper Sandler
    More analyst ratings

    $KRMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by President and CEO Tharby Linda M

    4 - KORU Medical Systems, Inc. (0000704440) (Issuer)

    8/11/25 4:26:24 PM ET
    $KRMD
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Chief Operating Officer Pazdan Christopher

    4 - KORU Medical Systems, Inc. (0000704440) (Issuer)

    8/11/25 4:25:19 PM ET
    $KRMD
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Chief Financial Officer Adams Thomas Edward

    4 - KORU Medical Systems, Inc. (0000704440) (Issuer)

    8/11/25 4:24:02 PM ET
    $KRMD
    Medical/Dental Instruments
    Health Care

    $KRMD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    KORU Medical Systems Announces Q2 2025 Financial Results, Including Record Double-digit Revenue, and Raises 2025 Revenue Guidance

    KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today reported financial results for the second quarter ended June 30, 2025. Financial Highlights •   Second quarter 2025 net revenues of $10.2 million, a 21% increase over the prior year period       •   Core business (Domestic and International) net revenues of $9.3 million, a 19% increase over the prior year period       •   Pharma Services and Clinical Trials (PST) net revenues of $0.9 mi

    8/6/25 4:05:00 PM ET
    $KRMD
    Medical/Dental Instruments
    Health Care

    KORU Medical Systems Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced inducement equity awards to Adam Kalbermatten, Chief Commercial Officer, pursuant to his previously announced employment agreement with the Company dated as of June 30, 2025. Mr. Kalbermatten was granted nonqualified stock options on August 1, 2025 to purchase 600,000 shares of the Company's common stock at an exercise price of $3.44 per share. In addition, on July 28, 2025, his start date, Mr. Kalbermatten received 300

    8/1/25 4:55:00 PM ET
    $KRMD
    Medical/Dental Instruments
    Health Care

    KORU Medical Systems to Participate in the Canaccord Genuity 45th Annual Growth Conference

    KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the company will participate in the Canaccord Genuity 45th Annual Growth Conference on August 13th, 2025. KORU Medical's management is scheduled to present at the Canaccord Genuity 45th Annual Growth Conference on August 13, 2025, at 10:30 am ET. Interested parties can access the live and archived webcast on the News/Events page of the Investors section of KORU Medical's website at www.korumedical.com. About KORU

    7/30/25 4:05:00 PM ET
    $KRMD
    Medical/Dental Instruments
    Health Care

    $KRMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    KORU Medical Systems downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded KORU Medical Systems from Overweight to Neutral and set a new price target of $4.50

    2/14/25 8:08:51 AM ET
    $KRMD
    Medical/Dental Instruments
    Health Care

    B. Riley Securities resumed coverage on KORU Medical Systems with a new price target

    B. Riley Securities resumed coverage of KORU Medical Systems with a rating of Buy and set a new price target of $4.00

    7/25/24 8:28:49 AM ET
    $KRMD
    Medical/Dental Instruments
    Health Care

    Lake Street initiated coverage on KORU Medical Systems with a new price target

    Lake Street initiated coverage of KORU Medical Systems with a rating of Buy and set a new price target of $4.00

    9/7/23 9:12:10 AM ET
    $KRMD
    Medical/Dental Instruments
    Health Care

    $KRMD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Manko Joseph M. Jr. bought $349,999 worth of shares (145,833 units at $2.40) and sold $349,999 worth of shares (145,833 units at $2.40) (SEC Form 4)

    4 - KORU Medical Systems, Inc. (0000704440) (Issuer)

    12/15/23 4:05:24 PM ET
    $KRMD
    Medical/Dental Instruments
    Health Care

    $KRMD
    SEC Filings

    View All

    SEC Form S-8 filed by KORU Medical Systems Inc.

    S-8 - KORU Medical Systems, Inc. (0000704440) (Filer)

    8/12/25 6:54:59 PM ET
    $KRMD
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by KORU Medical Systems Inc.

    10-Q - KORU Medical Systems, Inc. (0000704440) (Filer)

    8/6/25 4:11:41 PM ET
    $KRMD
    Medical/Dental Instruments
    Health Care

    KORU Medical Systems Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - KORU Medical Systems, Inc. (0000704440) (Filer)

    8/6/25 4:08:43 PM ET
    $KRMD
    Medical/Dental Instruments
    Health Care

    $KRMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by KORU Medical Systems Inc.

    SC 13G/A - KORU Medical Systems, Inc. (0000704440) (Subject)

    11/14/24 7:00:30 AM ET
    $KRMD
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by KORU Medical Systems Inc.

    SC 13G/A - KORU Medical Systems, Inc. (0000704440) (Subject)

    11/13/24 4:23:54 PM ET
    $KRMD
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by KORU Medical Systems Inc.

    SC 13G - KORU Medical Systems, Inc. (0000704440) (Subject)

    5/23/24 7:00:28 AM ET
    $KRMD
    Medical/Dental Instruments
    Health Care

    $KRMD
    Leadership Updates

    Live Leadership Updates

    View All

    KORU Medical Systems Appoints Adam Kalbermatten as Chief Commercial Officer

    KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty subcutaneous infusion solutions that improve quality of life for patients, today announced the appointment of Adam Kalbermatten as Chief Commercial Officer, effective July 28, 2025. Adam brings over two decades of commercial leadership experience in the medical device and pharmaceutical industries, with a proven track record of scaling businesses, building high-performing teams, and delivering customer-focused innovation. As Chief Commercial Officer, he will oversee all aspe

    7/7/25 4:05:00 PM ET
    $KRMD
    Medical/Dental Instruments
    Health Care

    KORU Medical Systems to Join Russell 3000® and Russell 2000® Indexes

    KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company is set to join the broad-market Russell 3000® Index and the small-cap Russell 2000® Index at the conclusion of the Russell indexes annual reconstitution, effective after the US market opens on June 30, 2025, according to a preliminary list of additions posted Friday, June 6, 2025. The annual reconstitution of the Russell US indexes captures the 4,000 largest US stocks as of April 30, ranking them by tot

    6/11/25 4:05:00 PM ET
    $KRMD
    Medical/Dental Instruments
    Health Care

    KORU Medical Systems, Inc. Appoints Ken Miller as Chief Commercial Officer

    KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty subcutaneous infusion solutions that improve quality of life for patients, today announced the appointment of Ken Miller as Chief Commercial Officer, effective November 6, 2023. Ken brings over 30 years of extensive expertise and experience in leading high-performing teams in commercialization and marketing strategy, international expansion, and driving sustainable growth and profitability. As Chief Commercial Officer, Ken will have oversight of the global commercial functio

    11/8/23 4:08:00 PM ET
    $BDX
    $KRMD
    Medical/Dental Instruments
    Health Care

    $KRMD
    Financials

    Live finance-specific insights

    View All

    KORU Medical Systems Announces Q2 2025 Financial Results, Including Record Double-digit Revenue, and Raises 2025 Revenue Guidance

    KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today reported financial results for the second quarter ended June 30, 2025. Financial Highlights •   Second quarter 2025 net revenues of $10.2 million, a 21% increase over the prior year period       •   Core business (Domestic and International) net revenues of $9.3 million, a 19% increase over the prior year period       •   Pharma Services and Clinical Trials (PST) net revenues of $0.9 mi

    8/6/25 4:05:00 PM ET
    $KRMD
    Medical/Dental Instruments
    Health Care

    KORU Medical Systems to Report Second Quarter 2025 Financial Results on August 6, 2025

    KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company will report second quarter 2025 financial results on Wednesday, August 6, 2025. KORU Medical's management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. Conference Call and Webcast Details The conference call can be accessed by dialing (877)-407-0784 for participants in the U.S. or Canada and (201)-689-8560 for internationa

    7/16/25 4:05:00 PM ET
    $KRMD
    Medical/Dental Instruments
    Health Care

    KORU Medical Systems Announces Record Q1 2025 Financial Results and Raises 2025 Revenue Guidance

    KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today reported financial results for the first quarter ended March 31, 2025. Recent Highlights First quarter 2025 net revenues of $9.6 million, an 18% increase over the prior year period Core business (Domestic and International) net revenues of $9.4 million, a 21% increase over the prior year period Gross profit of $6.0 million, a 19% increase over the prior year period, and gross margin of 62.8%, a 50-basis point improvement over th

    5/7/25 4:05:00 PM ET
    $KRMD
    Medical/Dental Instruments
    Health Care